Aquestive Therapeutics, Inc. (AQST) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 10 Buy.
The consensus price target is $10.00 (low: $6.00, high: $12.00), representing an upside of 141% from the current price $4.15.
Analysts estimate Earnings Per Share (EPS) of $-0.44 and revenue of $0.06B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.51 vs est $-0.44 (missed -16.9%). 2025: actual $-0.76 vs est $-0.62 (missed -22.8%). Analyst accuracy: 83%.
AQST Stock — 12-Month Price Forecast
$10.00
▲ +140.96% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Aquestive Therapeutics, Inc., the average price target is $10.00, with a high forecast of $12.00, and a low forecast of $6.00.
The average price target represents a +140.96% change from the last price of $4.15.
Highest Price Target
$12.00
Average Price Target
$10.00
Lowest Price Target
$6.00
AQST Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Aquestive Therapeutics, Inc. in the past 3 months
EPS Estimates — AQST
83%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.51
vs Est –$0.44
▼ 14.5% off
2025
Actual –$0.76
vs Est –$0.62
▼ 18.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — AQST
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.058B
vs Est $0.059B
▼ 2.2% off
2025
Actual $0.045B
vs Est $0.045B
▼ 0.6% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
